Pharmacological and Clinical Data

EjectDelay Clinical Efficacy


PRIMARY CLINICAL ENDPOINT

Ejaculatory Latency Time – ELT* (2005)

PE population: 1.8 minutes
Normal: 7.3 minutes

EjectDelay Clinical Efficacy-I-ELT

 

Source: Dapoxetine PI

Conclusion

Benzocaine 7.5% results in a higher efficacy (I-ELT time) than topical Lidocaine or oral Dapoxetine

EjectDelay Clinical Efficacy-I-ELT >2min


 

Conclusion

Benzocaine 7.5% results in a higher efficacy (I-ELT time) than topical Lidocaine or oral Dapoxetine

Dapoxetine vs. Topical Benzocaine Systemic Side


Effects

% of subjects who experienced various adverse effects from taking Dapoxetine vs. topical Benzocaine 7.5%

AEs Dapoxetine 30 mg Dapoxetine 60 mg Dapoxetine Placebo Benzocaine 7.5% Topical
Nausea 11.0 22.2 2.2 0
Dizziness 5.8 10.9 2.2 0
Headache 5.6 8.8 4.8 0
Diarrhea 3.5 6.9 1.7 0
Somnolence 3.1 4.7 0.5 0
Fatigue 2.0 4.1 1.2 0
Insomnia 2.1 3.9 1.5 0
Nasopharyngitis 3.2 2.9 2.3 0
Source: Dapoxetine PI

EjectDelay Clinical Efficacy-Damrau Trial


   

Conclusion

Benzocaine 5% results in a 2.9min increase in efficacy (I-ELT time) with a 100% response rate
Source: Damrau et al. J. Urology June 1963

Pharmacological and Clinical Data - PE Drugs - OTC Pharmacy
EjectDelay® is an over-the-counter (OTC) FDA compliant medicine used for the delay of premature ejaculation in men.

IMPORTANT SAFETY INFORMATION BELOW.

Do not use EjectDelay® if you are allergic to benzocaine. Discuss your general health status with your doctor to ensure that you are healthy enough to engage in sexual activity. If you experience discomfort during sex, seek immediate medical help. EjectDelay® should not be used with other PE treatments. EjectDelay® should not be used with any topical product containing lidocaine. EjectDelay® does not protect against sexually transmitted diseases, including HIV. Read the potential side effects before using EjectDelay®.